A 58-year-old man with a 12-year history of type 2 diabetes mellitus presents to the nephrology clinic. He reports progressive fatigue and mild dyspnea on exertion over the past 3 months. Blood pressure is 148/92 mmHg. Laboratory investigations show: serum creatinine 2.8 mg/dL, blood urea nitrogen 64 mg/dL, eGFR 22 mL/min/1.73 m², serum potassium 5.8 mEq/L, serum phosphate 4.2 mg/dL, serum calcium 8.1 mg/dL, and hemoglobin 9.2 g/dL. Urinalysis reveals 3+ proteinuria. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Assessment This patient presents with **Stage 4 CKD** (eGFR 15–29 mL/min/1.73 m²) secondary to diabetic nephropathy, with evidence of: - Progressive renal dysfunction (serum creatinine 2.8 mg/dL) - Proteinuria (3+) - Anemia of CKD (Hb 9.2 g/dL) - Hyperkalemia (K⁺ 5.8 mEq/L) - Hyperphosphatemia (PO₄ 4.2 mg/dL) - Hypocalcemia (Ca²⁺ 8.1 mg/dL) - Hypertension ## Management Principles at Stage 4 CKD **Key Point:** The goal at Stage 4 CKD is to **slow progression**, manage complications, and **prepare for renal replacement therapy**—not to initiate dialysis unless there are absolute indications (severe uremia, uncontrolled hyperkalemia, pulmonary edema, pericarditis). ### Optimal Interventions 1. **SGLT2 Inhibitors** — Demonstrated cardio-renal protection in diabetic CKD; reduce proteinuria and slow eGFR decline [cite:KDIGO 2022 Clinical Practice Guideline] 2. **ACE-I/ARB Optimization** — Cornerstone of renoprotection; reduce intraglomerular pressure and proteinuria 3. **Renal Replacement Therapy (RRT) Planning** — At eGFR <30 mL/min/1.73 m², patient education, vascular access creation, and modality selection should begin 4. **Anemia Management** — Target Hb 10–12 g/dL (NOT 13 g/dL); higher targets increase thrombotic risk without mortality benefit 5. **Mineral-Bone Disorder Management** — Phosphate binders, vitamin D analogs, and calcimimetics as needed ## Why This Answer Is Correct **High-Yield:** Option 1 (immediate ESA to Hb 13 g/dL) is **inappropriate** — current guidelines recommend target Hb 10–12 g/dL in CKD to avoid thrombotic complications. Option 3 (loop diuretics as primary therapy) is suboptimal without addressing the underlying renal disease progression. Option 4 (urgent dialysis) is premature — the patient has mild symptoms and no absolute indications (no pericarditis, severe hyperkalemia, or pulmonary edema). **Clinical Pearl:** SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) have become **first-line agents** in diabetic CKD regardless of glycemic control, due to their independent renoprotective and cardioprotective effects. ## Monitoring & Follow-up - Recheck electrolytes, eGFR, and phosphate monthly - Create arteriovenous fistula or plan peritoneal dialysis access when eGFR approaches 15 mL/min/1.73 m² - Educate on dietary sodium, potassium, and phosphate restriction - Screen for cardiovascular disease and bone disease